HealthDay News — For patients undergoing drug-eluting stent placement, there is a high rate of clopidogrel nonadherence, according to a study published in the February 15 issue of The American Journal of Cardiology.

Houman Khalili, MD, from the University of Texas Southwestern Medical Center in Dallas, and colleagues retrospectively collected one-year refill data from a pharmacy system to examine clopidogrel adherence among patients who underwent drug-eluting stent placement. The cohort comprised 369 patients (34% female; 39% Hispanic, 26% white, and 26% African-American).

The researchers found that the primary outcome of time to failure to obtain a clopidogrel refill was 153 days. Cumulative failure to obtain at least one refill was 23, 52, and 68%, respectively, at the first refill, 6 months, and 1 year. Twenty-one percent of patients had 100% coverage, while 34% had a proportion of days covered (PDC) of less than 80%. No independent predictors of nonadherence (PDC <80 percent) were identified.

“In conclusion, we identified a high rate of clopidogrel nonadherence in a multiethnic urban poor patient population where clopidogrel was provided at discharge and at nominal cost thereafter,” the authors write. “In this cohort, prediction models of nonadherence performed poorly. Novel strategies are needed to address this important problem.”

One author disclosed financial ties to the diagnostics and medical technology industries.

Full Text (subscription or payment may be required)